End-of-day quote
Pakistan S.E.
06:00:00 2024-04-25 pm EDT
5-day change
1st Jan Change
222.5
PKR
-1.57%
-1.29%
+0.86%
Ferozsons Laboratories : Financial Results for the Quarter Ended 2022-09-30
October 24, 2022 at 12:30 am EDT
Ferozsons Laboratories Limite
Condensed Interim Unconsolidated Statement of Profit or Loss (Un-audited)
For the period ended 30 September 2022
First Quarter ended
30 September
30 September
2022
2021
---------------------- Rupees -----------------
Revenue - net
2,286,494,656
1,693,186,215
Cost of sales
(1,292,816,834)
(866,753,209)
Gross profit
993,677,822
826,433,006
Administrative expenses
(152,262,244)
(121,844,633)
Selling and distribution expenses
(560,879,547)
(429,967,799)
Other expenses
(147,687,629)
(97,614,705)
Other income
44,622,436
46,052,929
Profit from operations
177,470,838
223,058,798
Finance cost
(20,377,337)
(3,841,214)
Profit before taxation
157,093,501
219,217,584
Taxation
(52,175,930)
(58,817,631)
Profit after taxation
104,917,571
160,399,953
Earnings per share - basic and diluted
Re-stated
2.41
3.69
Ferozsons Laboratories Limited
Condensed Interim Consolidated Statement of Profit or Loss (Un-audited)
For the period ended 30 September 2022
First Quarter ended
30 September
30 September
2022
2021
---------------------- Rupees ----------------------
Revenue - net
2,566,996,821
2,223,282,284
Cost of sales
(1,489,924,570)
(1,198,797,940)
Gross profit
1,077,072,251
1,024,484,344
Administrative expenses
(171,584,475)
(136,219,020)
Selling and distribution expenses
(611,189,254)
(462,665,538)
Other expenses
(144,245,078)
(108,494,121)
Other income
74,642,779
90,751,221
Profit from operations
224,696,223
407,856,886
Finance cost
(34,670,058)
(27,192,799)
Profit before taxation
190,026,165
380,664,087
Taxation
(57,831,868)
(79,674,096)
Profit after taxation
132,194,297
300,989,991
Attributable to:
Owners of the Group
126,334,743
273,431,879
Non-controlling interests
5,859,554
27,558,112
Profit after taxation
132,194,297
300,989,991
Earnings per share - basic and diluted
2.91
Re-stated
6.29
Attachments
Original Link
Original Document
Permalink
Disclaimer
Ferozsons Laboratories Ltd. published this content on 24 October 2022 and is solely responsible for the information contained therein. Distributed by Public , unedited and unaltered, on 24 October 2022 04:29:01 UTC .
Ferozsons Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023
Feb. 28
CI
Ferozsons Laboratories Limited Reports Earnings Results for the First Quarter Ended September 30, 2023
23-10-29
CI
Ferozsons Laboratories Limited Reports Earnings Results for the Full Year Ended June 30, 2023
23-10-07
CI
Ferozsons Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023
23-04-26
CI
Ferozsons Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022
23-02-28
CI
Ferozsons Laboratories Limited Reports Earnings Results for the First Quarter Ended September 30, 2022
22-10-31
CI
Ferozsons Laboratories Limited Reports Earnings Results for the Full Year Ended June 30, 2022
22-09-08
CI
Ferozsons Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2022
22-04-25
CI
Ferozsons Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2021
22-02-06
CI
Ferozsons Laboratories Limited Reports Earnings Results for the First Quarter Ended September 30, 2021
21-10-26
CI
Ferozsons Laboratories Limited Reports Earnings Results for the Full Year Ended June 30, 2021
21-08-31
CI
Ferozsons Laboratories Limited Reports Earnings Results for the Third Quarter Ended March 31, 2021
21-04-26
CI
Ferozsons Laboratories Limited Reports Earnings Results for the Second Quarter Ended December 31, 2020
21-01-29
CI
Ferozsons Laboratories Limited Proposes the Final Cash Dividend for the Year Ended 30 June 2020
20-10-04
CI
Ferozsons Laboratories Limited Reports Earnings Results for the Full Year Ended June 30, 2020
20-09-24
CI
Gilead Sciences : India sees record 49,000 new coronavirus cases, drug shortages in places
20-07-24
RE
Pakistan's Ferozsons to begin producing COVID-19 drug remdesivir
20-05-15
RE
Gilead Sciences, Inc. Signs Licensing Agreements with Cipla Limited, Hetero Labs Limited, Jubilant Life Sciences Limited, Mylan, Inc. and Ferozsons Laboratories Limited to Manufacture and Distribute Remdesivir in 127 Countries
20-05-13
CI
Mylan N : Gilead ties up with generic drugmakers for COVID-19 drug supply
20-05-12
RE
Mylan N : Gilead ties up with generic drugmakers for COVID-19 drug supply
20-05-12
RE
Ferozsons Laboratories Limited Reports Earnings Results for the Third Quarter Ended March 31, 2020
20-04-29
CI
Ferozsons Laboratories Limited Approves an Interim Cash Dividend for the Six Months Ended 31 December 2019
20-02-28
CI
Ferozsons Laboratories Limited Reports Earnings Results for the Second Quarter Ended December 31, 2019
20-02-28
CI
Ferozsons Laboratories Ltd. Reports Earnings Results for the First Quarter Ended September 30, 2019
19-10-25
CI
Ferozsons Laboratories Limited Announces Final Cash Dividend
19-09-23
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Ferozsons Laboratories Limited is a Pakistan-based holding company. The Company is primarily engaged in the importing, manufacturing and sale of pharmaceutical products and medical devices. The Company possesses brands in the areas of gastroenterology, hepatology, cardiology, and oncology, with an emerging presence in endocrinology as well as mother and child health the diabetes space. The Company offers a range of medical devices in the areas of cardiology, electrophysiology, endoscopy, gastroenterology, pulmonology, urology, and peripheral interventions. Its product portfolio includes pharmaceuticals, medical technologies, and export. The Companyâs export markets are spread across Asia, Africa, and the Central Asian region. The Company's subsidiaries include BF Biosciences Limited, which is engaged in the import, manufacturing, and sale of pharmaceutical products and Farmacia, which is engaged in the sale and distribution of medicines and other related products.
More about the company
Last Close Price
222.5
PKR
Average target price
325
PKR
Spread / Average Target
+46.04%
Consensus
1st Jan change
Capi.
+0.86% 34.74M +25.83% 661B +27.00% 566B -6.76% 352B +20.34% 332B +3.00% 283B +13.09% 231B +5.46% 200B -9.61% 195B -6.26% 145B
Other Pharmaceuticals
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1